#USA #Upsher-Smith #Maple Grove #Bora Pharmaceuticals #Glatiramer

Upsher-Smith Laboratories Expands Portfolio with Glatiramer Acetate Injection

Upsher-Smith Laboratories, LLC, a subsidiary of Bora Pharmaceuticals Co., Ltd., recently announced its latest addition to the company's pharmaceutical lineup: Glatiramer Acetate Injection. This product will be available in two concentrations, 20 mg/mL and 40 mg/mL, and is expected to enhance the company's offerings in the complex generic medications market. With approximately $562 million in annual sales for Glatiramer Acetate injections, as reported by IQVIA, this launch represents a significant step forward for the company.

What Is Glatiramer Acetate Injection?

Glatiramer Acetate is primarily used in the treatment of multiple sclerosis (MS), a chronic illness affecting the central nervous system. The generic version introduced by Upsher-Smith is designated with a Therapeutic Equivalence (TE) code of AP. This aligns it as a substitute for the well-known brand COPAXONE®, manufactured by Teva Pharmaceutical Industries, thereby giving patients more options for their treatment.

A Commitment to Quality and Access

Jim Maahs, Senior Vice President and Head of Upsher-Smith Commercial, highlighted the importance of this product launch, stating that it significantly advances the company's goal to diversify its complex generic medicine offerings. The introduction of this generic is a testament to Upsher-Smith's commitment to providing high-quality, affordable medications to patients facing complex neurological conditions.

Product Specifications

Here are key details regarding the available strengths and packaging of Glatiramer Acetate Injection:

• - Product: Glatiramer Acetate Injection

Strength: 20 mg/mL
NDC #: 0832-6084-30
Size/Package: 30 single-dose, prefilled syringes

• - Product: Glatiramer Acetate Injection

Strength: 40 mg/mL
NDC #: 0832-6085-12
Size/Package: 12 single-dose, prefilled syringes

For those interested in ordering, Upsher-Smith can be reached at 1-800-654-2299 for further inquiries.

Safety Precautions

As with any medication, there are important safety considerations associated with Glatiramer Acetate Injection. The company has issued warnings regarding the possibility of anaphylactic reactions, which can occur at any time during treatment, even after years. Patients are encouraged to familiarize themselves with the symptoms of anaphylaxis to ensure prompt responses to any adverse reactions.

Upsher-Smith's Vision and Future

Upsher-Smith has long been recognized as a reliable pharmaceutical provider in the U.S., focusing on the health and wellness of patients through the delivery of high-quality products. As part of Bora Pharmaceuticals, the company is committed to sustainable growth and innovation in their pharmaceutical offerings. By expanding their product line, they aim to meet the diverse needs of patients and healthcare providers alike.

For additional information or queries regarding Glatiramer Acetate Injection, healthcare providers can access full prescribing information or contact their customer service for guidance. Upsher-Smith’s commitment to improving the quality of life for patients continues to drive their mission in the pharmaceutical landscape.